Flag of the European Union EU Clinical Trials Register Help

Clinical trials for apixaban OR rivaroxaban OR dabigatran OR edoxaban

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    244 result(s) found for: apixaban OR rivaroxaban OR dabigatran OR edoxaban. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-003569-91 Sponsor Protocol Number: NL62896 Start Date*: 2017-12-08
    Sponsor Name:Hagaziekenhuis
    Full Title: The effect of body weight on trough concentrations of DOACs in patients.
    Medical condition: No medical condition will be investigated. This study will only investigate the effect of body weight on through concentrations of direct oral anticoagulants (DOACs)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002105-18 Sponsor Protocol Number: 333336666666666699 Start Date*: 2017-05-04
    Sponsor Name:Helsinki City Hospital Haartman
    Full Title: Laboratory measurement of direct oral anticoagulants on patients with atrial fibrillation
    Medical condition: Non-valvular atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003361-19 Sponsor Protocol Number: H-19078792 Start Date*: 2020-09-07
    Sponsor Name:Rigshospitalet
    Full Title: Prospective study on the impact of different anti-thrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter bioprosthetic aortic valves The Nordic Aortic Val...
    Medical condition: Patients who have undergone successful transcatheter bioprosthetic aortic valve implantation (TAVI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10077017 TAVI LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000753-45 Sponsor Protocol Number: NAVIT-18 Start Date*: 2018-11-11
    Sponsor Name:NAVARRBIOMED-FUNDACION MIGUEL SERVET
    Full Title: Vitreretinal surgery with and without oral anticoagulants: surgical complications, visual results and perioperative thromboembolic events.
    Medical condition: Patients undergoing vitreoretinal surgery under treatment with oral anticoagulants
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001759-38 Sponsor Protocol Number: K675 Start Date*: 2019-12-04
    Sponsor Name:Ruprecht-Karls University Heidelberg Medical Faculty, University Hospital represented in law by its commercial director
    Full Title: Pharmacokinetics of a microdosed cocktail containing rivaroxaban, apixaban and edoxaban in children with congenital heart defects
    Medical condition: 20 children with non-cyanotic congenital heart defects especially atrial septal defects (ASD) and ventricular septal defects (VSD) in admitted to the paediatric cardiology wards will be included. T...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003621-28 Sponsor Protocol Number: 5072018 Start Date*: 2019-07-23
    Sponsor Name:IUCPQ
    Full Title: Short-Term Anticoagulation versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES study.
    Medical condition: Device thrombosis at 2 months and 12 months after left atrial appendage closure (LAAC) Ischemic events (stroke, TIA) at 2-month and 1-, 2-, 3-, 4-and 5-year follow-up Bleeding events at 2-month an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10014523 Embolism and thrombosis HLGT
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    20.0 10047065 - Vascular disorders 10005103 Bleeding LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000058-21 Sponsor Protocol Number: CLOSURE-AF-DZHK16 Start Date*: 2018-03-01
    Sponsor Name:Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin
    Full Title: Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial
    Medical condition: Atrial Fibrillation with high risk of stroke and bleeding
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001336-62 Sponsor Protocol Number: 2019-ASPIREAF Start Date*: 2020-04-01
    Sponsor Name:Hamilton Health Sciences Corporation
    Full Title: Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial
    Medical condition: Perioperative atrial fibrillation after noncardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10042244 Stroke LLT
    20.0 100000004866 10005103 Bleeding LLT
    20.0 100000004849 10003663 Atrial flutter/ fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001418-12 Sponsor Protocol Number: NCT04483583 Start Date*: 2021-06-24
    Sponsor Name:University of Florida
    Full Title: Tailoring P2Y12 Inhibiting Therapy in Patients requiring Oral Anticoagulation after undergoing Percutaneous Coronary Intervention: The Switching Anti-Platelet and Anti-Coagulant Therapy – 2 Study
    Medical condition: Efficacy of antiplatelet therapy after percutaneous coronary intervention in patients using oral anticoagulants
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003890-40 Sponsor Protocol Number: 1160.204 Start Date*: 2015-02-24
    Sponsor Name:Boehringer Ingelheim Italia S.p.A.
    Full Title: Randomized Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial)
    Medical condition: Patients with non-valvular atrial fibrillation (NVAF) undergoing catheter ablation for atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    17.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    17.1 10042613 - Surgical and medical procedures 10043634 Thrombosis prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) NL (Completed) DE (Completed) BE (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001817-20 Sponsor Protocol Number: NL73805.100.20 Start Date*: 2021-05-07
    Sponsor Name:St. Antonius Hospital Nieuwegein, The Netherlands
    Full Title: Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation
    Medical condition: Thromboembolic, bleeding and vascular complications after transcatheter aortic valve implantation in patients using oral anticoagulants
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005022-18 Sponsor Protocol Number: PACeS Start Date*: 2022-07-26
    Sponsor Name:Icahn School of Medicine at Mount Sinai
    Full Title: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG
    Medical condition: New-Onset Post-Operative Atrial Fibrillation after CABG
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000393-11 Sponsor Protocol Number: NL60426 Start Date*: 2017-09-07
    Sponsor Name:University Medical Center utrecht
    Full Title: ’Switching anticoagulant management from a VKA to a NOAC-based treatment strategy in frail elderly patients with atrial fibrillation (FRAIL-AF study)
    Medical condition: Atrial Fibrilation
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001443-31 Sponsor Protocol Number: 1801 Start Date*: 2018-11-21
    Sponsor Name:Leiden University Medical Center
    Full Title: DOAC Levels prior to Incision study: DALI study
    Medical condition: No medical condition will be investigated. This study will only investigate DOAC levels during surgery. Patients who use DOACs are patients with venous thrombosis and atrial fibrillation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000236-34 Sponsor Protocol Number: ELAN Start Date*: 2019-02-26
    Sponsor Name:Inselspital (University Hospital) Bern
    Full Title: Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): an international, multicentre, randomised-controlled, two-arm, assessor...
    Medical condition: Recurrent strokes in patients with atrial fibrillation who suffered an ischaemic stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FI (Completed) BE (Completed) DE (Completed) SK (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002176-41 Sponsor Protocol Number: 17HH4268 Start Date*: 2019-09-03
    Sponsor Name:Imperial College of Science Technology and Medicine
    Full Title: PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF)
    Medical condition: Ischaemic stroke prevention in patients with atrial fibrillation and previous intracerebral haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10003661 Atrial fibrillation paroxysmal LLT
    20.0 100000004849 10034039 Paroxysmal atrial fibrillation LLT
    20.0 100000004849 10066551 Chronic atrial fibrillation LLT
    20.0 100000004849 10071668 Permanent atrial fibrillation LLT
    22.1 100000004852 10057613 Thromboembolic stroke LLT
    21.1 100000004852 10022754 Intracerebral hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) AT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000315-24 Sponsor Protocol Number: 1208182 Start Date*: 2013-06-18
    Sponsor Name:CHU SAINT-ETIENNE
    Full Title: Pharmaco-epidemiology of the treatment of the symptomatic pulmonary embolism among in-patients and 75 years old or more: prospective, multicentric "PEAGE" cohort
    Medical condition: Symptomatic pulmunory embolism on patients over 75 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037379 Pulmonary embolism and thrombosis HLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002263-96 Sponsor Protocol Number: 39486 Start Date*: 2012-07-11
    Sponsor Name:MUMC
    Full Title: dabigatran and rivaroxaban: prediction of anticoagulant effect
    Medical condition: non valvular atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002620-17 Sponsor Protocol Number: 18-513 Start Date*: 2019-01-08
    Sponsor Name:Portola Pharmaceuticals, Inc
    Full Title: A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR
    Medical condition: Oral FXa inhibitor-treated patients with acute intracranial bleeding.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10075279 Anticoagulant reversal therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) NL (Completed) ES (Prematurely Ended) GR (Completed) CZ (Completed) LV (Completed) FI (Prematurely Ended) NO (Prematurely Ended) LT (Prematurely Ended) PL (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003852-19 Sponsor Protocol Number: DOAC Start Date*: 2019-03-29
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: An Open Label, Non-Randomised, Phase IV Clinical Trial to Determine the Transfer of Apixaban and Rivaroxaban in Breast Milk Following Oral Administration
    Medical condition: healthy volunteers (Venous Thromboembolism)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:40:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA